Highlights
- 1
- 2Leukemia · 2021
- 3
Publications
65 publications
Funding
3 grants
Active
2 grants- PISRA 250998-01Sponsor Research Agreement with Dr. Abu-Zeinah and Pharma&pharmaand GmbH · 2025–2027Contract
- PIASH 233462-03Predicting risk of disease progression in polycythemia vera (PV): development and validation of a highly predictive dynamic model using machine learning and rich data from automated extraction of medical records and a novel informatics pipelineAmerican Society of Hematology Inc · 2024–2027
Completed grants (1)
- MPIUL1TR002384-01Clinical and Translational Science Center - UL1National Center for Advancing Translational Sciences · 2017–2022
Clinical research
6 studies
Active
1 study- PINCT06661915A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)PHASE2 · National Cancer Institute · OPEN TO ACCRUAL (as of 2026)Accelerated Phase Myeloproliferative Neoplasm; Blast Phase Myeloproliferative Neoplasm; Essential Thrombocythemia; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Not Otherwise Specified; Polycythemia Vera; Primary Myelofibrosis; Secondary Myelofibrosis
Completed & closed trials (5)
- PINCT06468033A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b (P1101) in Adult Patients With Pre-fibrotic/Early Primary Myelofibrosis (PMF) or Overt PMF at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension StudyPHASE3 · PharmaEssentia · CLOSED TO ACCRUAL (as of 2026)Primary Myelofibrosis; Myeloproliferative Neoplasm
- PICompassionate Use of Momelotinib for Treatment of Myelofibrosis in Patient L-NWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
- PINCT05482971A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential ThrombocythemiaPHASE2 · PharmaEssentia · CLOSED TO ACCRUAL (as of 2024)Essential Thrombocythemia
- PINCT04285086A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.PHASE3 · PharmaEssentia · IRB STUDY CLOSURE (as of 2023)Essential Thrombocythemia
- PIClinical and Biological Responses to COVID-19 Vaccination in Patients with Myeloproliferative NeoplasmsWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
External relationships
Leadership Roles
Cancer Research & Treatment Fund Inc
Ownership
Dr AZ Consulting LLC
Advisory/Scientific Board Member
PharmaEssentia · Silence Therapeutics PLC · Takeda Pharmaceutical Company Limited
Other
AlphaSights, Inc · AOP Health · Atheneum Partners · Cancer Research & Treatment Fund Inc · Cogent Biosciences, Inc. · Dr AZ Consulting LLC · Gerson Lehrman Group (GLG) · Guidepoint Global LLC · Incyte Corporation · Inlightened INC · PharmaEssentia · Slingshot Insights Inc · Sobi INC · Takeda Pharmaceutical Company Limited